PierianDx raises $27M in Series B to ‘democratize’ next-generation sequencing
The startup describes its software as providing clinical labs with more streamlined and accurate analysis, interpretation and reporting for accelerating personalized medicine programs.
A startup that aims to provide a software-as-a-service platform to allow genomic sequencing as a standard of care has raised its latest round of financing.
St. Louis-based PierianDx said that it had closed a $27 million Series B funding round, led by ATW Partners and SJW Ventures, along with existing investors Health Catalyst Capital, Inova health Systems, RTI International and ARUP Laboratories. The company closed its Series A round, for $9.3 million, in January 2016.